Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohnʼs Disease

Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings

(2016) F. Iannone et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial

(2016) Remo Panaccione et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

(2014) C. Ma et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment

(2014) M. R. K. L. Lie et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease

(2014) Mamoru Watanabe et al.   Journal of Crohns & Colitis

Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study

(2014) Christopher Ma et al.   Journal of Crohns & Colitis

Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients

(2014) Charlotte P. Peters et al.   Journal of Crohns & Colitis

Sex differences in pain: a brief review of clinical and experimental findings

(2013) E.J. Bartley et al.   BRITISH JOURNAL OF ANAESTHESIA

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

(2012) Mirthe Emilie van der Valk et al.   GUT

Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease

(2012) Zuzana Zelinkova   WORLD JOURNAL OF GASTROENTEROLOGY

High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy

(2011) Z. Zelinkova et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Predictors of adalimumab dose escalation in patients with crohnʼs disease at a tertiary referral center

(2011) Russell D. Cohen et al.   INFLAMMATORY BOWEL DISEASES

Systematic Assessment of Factors Influencing Preferences of Crohnʼs Disease Patients in Selecting an Anti-Tumor Necrosis Factor Agent (CHOOSE TNF TRIAL)

(2011) Stephan R. Vavricka et al.   INFLAMMATORY BOWEL DISEASES

Long-term durability of response to adalimumab in Crohnʼs disease

(2011) M. Chaparro et al.   INFLAMMATORY BOWEL DISEASES

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

(2009) Konstantinos Karmiris et al.   GASTROENTEROLOGY

Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients

(2008) A. SWAMINATH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience

(2008) A. OUSSALAH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

(2008) Jian-Feng Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY